ARG1 and neoplasm: These findings support the hypothesis that ARG1/2 inhibition in tumor cells and MDMs can enhance the immune response by restoring metabolic conditions favorable for T and NK cell activity, thereby increasing the efficacy of immunotherapeutic agents such as PD-1 inhibitors.